The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
Published version of a preprint
Abstract
Mutation-associated neoantigens (MANA) are a target of antitumor T-cell immunity. Sensitive, simple, and standardized assays are needed to assess the repertoire of functional MANA-specific T cells in oncology. Assays analyzing in vitro cytokine production such as ELISpot and intracellular cytokine staining have been useful but have limited sensitivity in assessing tumor-specific T-cell responses and do not analyze antigen-specific T-cell repertoires. The FEST (Functional Expansion of Specific T cells) assay described herein integrates T-cell receptor sequencing of short-term, peptide-stimulated cultures with a bioinformatic platform to identify antigen-specific clonotypic amplifications. This assay can be adapted for all types of antigens, including MANAs via tumor exome-guided prediction of MANAs. Following in vitro identification by the MANAFEST assay, the MANA-specific CDR3 sequence can be used as a molecular barcode to detect and monitor the dynamics of these clonotypes in blood, tumor, and normal tissue of patients receiving immunotherapy. MANAFEST is compatible with high-throughput routine clinical and lab practices. Cancer Immunol Res; 6(8); 888–99. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutant p53 is hydrolyzed intracellularly to produce a peptide known as a mutation-associated neoantigen that can be presented on the cell surface after forming a complex (pHLA) with human leukocyte antigen (HLA) proteins.528,529”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [528]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Self-citationNeoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Self-citationCouzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051 · cited 6×
“We therefore sought to determine (1) the optimal number of starting T cells required to capture the breadth of the antigen-specific repertoire and (2) the lower limit peptide concentration that”
BackgroundMethodInfluentialIdentifying specificity groups in the T cell receptor repertoire
Glanville, J., Huang, H., Nau, A., Hatton, O., Wagar, L. E., Rubelt, F., Ji, X., Han, A., Krams, S. M., Pettus, C., et al. (2017) · Nature · doi:10.1038/nature22976 · Cited by 1,026
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479
Self-citation
Research works printed but not linked: 42
- Lu, 2016, Targeting neoantigens for cancer immunotherapy, Int Immunol, 28, 365, 10.1093/intimm/dxw026 · DOI
- Yee, 2002, Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses, Nat Rev Cancer, 2, 409, 10.1038/nrc820 · DOI
- Moodie, 2010, Response definition criteria for ELISPOT assays revisited, Cancer Immunol Immunother, 59, 1489, 10.1007/s00262-010-0875-4 · DOI · Paper page
- Craig, 2008, Flow cytometric immunophenotyping for hematologic neoplasms, Blood, 111, 3941, 10.1182/blood-2007-11-120535 · DOI · Paper page
- Meyer, 2000, Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers, Proc Natl Acad Sci USA, 97, 11433, 10.1073/pnas.190335897 · DOI
- Barnes, 2004, Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells, Eur J Immunol, 34, 1570, 10.1002/eji.200424898 · DOI
- Tran, 2015, Immunogenicity of somatic mutations in human gastrointestinal cancers, Science, 350, 1387, 10.1126/science.aad1253 · DOI · Paper page
- Lu, 2014, Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions, Clin Cancer Res, 20, 3401, 10.1158/1078-0432.CCR-14-0433 · DOI · Paper page
- Andersen, 2012, Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers, Nat Protoc, 7, 891, 10.1038/nprot.2012.037 · DOI
- Iezzi, 1998, The duration of antigenic stimulation determines the fate of naive and effector T cells, Immunity, 8, 89, 10.1016/S1074-7613(00)80461-6 · DOI · Paper page
- Wells, 1997, Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response, J Clin Invest, 100, 3173, 10.1172/JCI119873 · DOI · Paper page
- Sun, 1999, Antigen-specific T cell activation and proliferation during oral tolerance induction, J Immunol, 162, 5868, 10.4049/jimmunol.162.10.5868 · DOI
- Carlson, 2013, Using synthetic templates to design an unbiased multiplex PCR assay, Nat Commun, 4, 2680, 10.1038/ncomms3680 · DOI · Paper page
- Robins, 2009, Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells, Blood, 114, 4099, 10.1182/blood-2009-04-217604 · DOI · Paper page
- Anagnostou, 2017, Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer, Cancer Discov, 7, 264, 10.1158/2159-8290.CD-16-0828 · DOI · Paper page
- Jones, 2015, Personalized genomic analyses for cancer mutation discovery and interpretation, Sci Transl Med, 7, 283ra53, 10.1126/scitranslmed.aaa7161 · DOI · Paper page
- Sausen, 2013, Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma, Nature genetics, 45, 12, 10.1038/ng.2493 · DOI · Paper page
- Szolek, 2014, OptiType: precision HLA typing from next-generation sequencing data, Bioinformatics, 30, 3310, 10.1093/bioinformatics/btu548 · DOI · Paper page
- Nielsen, 2016, NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets, Genome Med, 8, 33, 10.1186/s13073-016-0288-x · DOI · Paper page
- Lundegaard, 2008, NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11, Nucleic Acids Res, 36, W509, 10.1093/nar/gkn202 · DOI · Paper page
- Lundegaard, 2008, Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers, Bioinformatics, 24, 1397, 10.1093/bioinformatics/btn128 · DOI · Paper page
- Stranzl, 2010, NetCTLpan: pan-specific MHC class I pathway epitope predictions, Immunogenetics, 62, 357, 10.1007/s00251-010-0441-4 · DOI · Paper page
- Kim, 2009, Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior, BMC Bioinformatics, 10, 394, 10.1186/1471-2105-10-394 · DOI · Paper page
- Team, 2014, R: A language and environment for statistical computing
- Gentleman, 2004, Bioconductor: open software development for computational biology and bioinformatics, Genome Biol, 5, R80, 10.1186/gb-2004-5-10-r80 · DOI · Paper page
- Benjamini, 1995, Controlling the false discovery rate - a practical and powerful approach to multiple testing, J Roy Stat Soc B Met, 57, 289, 10.1111/j.2517-6161.1995.tb02031.x · DOI · Paper page
- Chang, 2017, shiny: Web Application Framework for R. R package version 1.0.0
- Price, 2009, Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection, J Exp Med, 206, 923, 10.1084/jem.20081127 · DOI
- Valkenburg, 2016, Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses, Proc Natl Acad Sci USA, 113, 4440, 10.1073/pnas.1603106113 · DOI
- Du, 2016, HIV-1-Specific CD8 T cells exhibit limited cross-reactivity during acute infection, J Immunol, 196, 3276, 10.4049/jimmunol.1502411 · DOI
- Kloverpris, 2015, CD8+ TCR bias and immunodominance in HIV-1 infection, J Immunol, 194, 5329, 10.4049/jimmunol.1400854 · DOI
- Hill, 2014, Epitope specificity delimits the functional capabilities of vaccine-induced CD8 T cell populations, J Immunol, 193, 5626, 10.4049/jimmunol.1401017 · DOI
- Sidney, 2001, Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules, Hum Immunol, 62, 1200, 10.1016/S0198-8859(01)00319-6 · DOI
- Rammensee, 1993, Peptides naturally presented by MHC class I molecules, Annu Rev Immunol, 11, 213, 10.1146/annurev.iy.11.040193.001241 · DOI · Paper page
- Motozono, 2014, Molecular basis of a dominant T cell response to an HIV reverse transcriptase 8-mer epitope presented by the protective allele HLA-B*51:01, J Immunol, 192, 3428, 10.4049/jimmunol.1302667 · doi:10.4049/jimmunol.1302667
- Wu, 2011, Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals, Proc Natl Acad Sci USA, 108, 9178, 10.1073/pnas.1105624108 · DOI
- Steven, 1997, Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response, J Exp Med, 185, 1605, 10.1084/jem.185.9.1605 · DOI · Paper page
- Betts, 2006, HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells, Blood, 107, 4781, 10.1182/blood-2005-12-4818 · DOI · Paper page
- Kirsch, 2015, T-cell receptor profiling in cancer, Mol Oncol, 9, 2063, 10.1016/j.molonc.2015.09.003 · DOI
- Pasetto, 2016, Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor, Cancer Immunol Res, 4, 734, 10.1158/2326-6066.CIR-16-0001 · DOI · Paper page
- Sidhom, 2017, ImmunoMap: a bioinformatics tool for T-cell repertoire analysis, Cancer Immunol Res, 6, 151, 10.1158/2326-6066.CIR-17-0114 · DOI
- Faham, 2017, Discovery of T-cell receptor beta motifs specific to HLA-B27(+) ankylosing spondylitis by deep repertoire sequence analysis, Arthritis Rheumatol, 69, 774, 10.1002/art.40028 · DOI
Cited by
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Cancer vaccines: the next immunotherapy frontier
Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. D. (2022) · Nature Cancer · doi:10.1038/s43018-022-00418-6 · Cited by 843
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Jackson, C. M., Choi, J., & Lim, M. (2019) · Nature Immunology · doi:10.1038/s41590-019-0433-y · Cited by 751
Metadata
- Authors
- Danilova, L., Anagnostou, V., Caushi, J. X., Sidhom, J.-W., Guo, H., Chan, H. Y., Suri, P., Tam, A., Zhang, J., Asmar, M. E., Marrone, K. A., Naidoo, J., Brahmer, J. R., Forde, P. M., Baras, A. S., Cope, L., Velculescu, V. E., Pardoll, D. M., Housseau, F., & Smith, K. N.
- Affiliations
- 1The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- ORCID
- Danilova, Ludmila
- Venue
- Cancer Immunology Research
- Published
- 2018-07-31
- Volume
- 6
- Issue
- 8
- Pages
- 888-899
- ISSN
- 2326-6066
- 2326-6074
- Cited by
- 168
- References
- 8
- Language
- en
- Funders
- NIH (R01 CA203891-01A1)
- National Institutes of Health (CA121113, CA180950)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0129
- The paper
- Danilova, L., Anagnostou, V., Caushi, J. X., Sidhom, J.-W., Guo, H., Chan, H. Y., Suri, P., Tam, A., Zhang, J., Asmar, M. E., Marrone, K. A., Naidoo, J., Brahmer, J. R., Forde, P. M., Baras, A. S., Cope, L., Velculescu, V. E., Pardoll, D. M., Housseau, F., & Smith, K. N. (2018). The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0129
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.